本文選題：ATG　切入點(diǎn)：急性細(xì)胞性排斥反應(yīng)　出處：《實(shí)用醫(yī)學(xué)雜志》2017年07期

【摘要】：目的:探討腎移植術(shù)后尿液中IP-10在ATG治療急性細(xì)胞性排斥反應(yīng)時(shí)劑量及療程評(píng)估方面的應(yīng)用價(jià)值。方法:收集腎移植術(shù)后病理確診為急性細(xì)胞性排斥反應(yīng)的患者40例,隨機(jī)將其分為IP-10組(n=20)和Scr組(n=20),測(cè)定此時(shí)兩組患者尿IP-10和Scr水平,之后給予ATG治療,并分別將IP-10和Scr水平變化作為ATG劑量調(diào)整依據(jù)及停藥標(biāo)準(zhǔn),觀察IP-10組和Scr組ATG療程、人均日劑量、人均總劑量、嚴(yán)重血小板及中性粒細(xì)胞減少發(fā)生率、3月內(nèi)急性排斥反應(yīng)再發(fā)生率、1年內(nèi)感染發(fā)生率。結(jié)果:平均用藥時(shí)間IP-10組(5.35±1.93)d,Scr組(6.70±1.75)d;人均ATG日劑量IP-10組(2.50±0.57)mg(/kg·d),Scr組(2.77±0.74)mg(/kg·d);人均ATG總劑量IP-10組(13.40±6.59)mg/kg,Scr組(18.25±7.35)mg/kg。三項(xiàng)指標(biāo)兩組間均存在顯著性差異(P0.05)。嚴(yán)重血小板及中性粒細(xì)胞減少發(fā)生率、3個(gè)月內(nèi)急性排斥反應(yīng)再發(fā)生率以及1年內(nèi)感染發(fā)生率兩組間無(wú)明顯差異(P0.05)。結(jié)論:尿IP-10檢測(cè)法能夠有效、可靠指導(dǎo)腎移植術(shù)后急性細(xì)胞性排斥反應(yīng)患者ATG使用,降低ATG治療費(fèi)用。
[Abstract]:Objective: to evaluate the value of IP-10 in urine after renal transplantation in the evaluation of dosage and course of treatment of acute cellular rejection with ATG.Methods: forty patients with acute cellular rejection after renal transplantation were randomly divided into IP-10 group (n = 20) and Scr group (n = 20). The levels of urinary IP-10 and Scr were measured, and then ATG was given.The changes of IP-10 and Scr levels were taken as the basis of ATG dose adjustment and withdrawal criteria, respectively. The course of ATG treatment, the daily dose per person and the total dose per capita in IP-10 group and Scr group were observed.The incidence of severe thrombocytopenia and neutropenia, acute rejection within 3 months and infection within 1 year.緇撴灉:騫沖潎鐢ㄨ嵂鏃墮棿IP-10緇，

本文編號(hào)：1710766